文献速递淋巴瘤

脾边缘区淋巴瘤组织学转化的临床生物学特征与结局

Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
PubMed 文献 · Br J Haematol · 2021-09-14

该研究纳入36例脾边缘区淋巴瘤伴组织学转化(SMZL-T)患者,含巴塞罗那医院84例SMZL队列中的15例及其他中心21例。

要点

  • SMZL患者5年组织学转化累积发生率为15%。

研究设计与样本

  • 研究描述了36例SMZL-T患者,包括巴塞罗那医院84例SMZL队列中的15例及其他中心诊断的21例SMZL-T。

主要发现

  • HCB队列5年转化累积发生率为15%。
  • 36例SMZL-T中1例发生霍奇金淋巴瘤,35例为弥漫大B细胞淋巴瘤,71%为非生发中心表型。
  • 主要特征为B症状、淋巴结肿大和高血清LDH。
  • 22例SMZL-T中12例(55%)见复杂核型,14例中6例(43%)FISH检出MYC、BCL2和/或BCL6异常。

关键数值与推荐

  • 21例接受免疫化疗,6例化疗,1例放疗,3例脾切除。

临床怎么用

  • 对SMZL患者应关注血细胞减少、低白蛋白血症、复杂核型及ILL/HPLL/ABC评分以评估转化风险。
  • SMZL-T治疗可采用免疫化疗等方案,达到完全缓解与更好生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0·05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4·025, P = 0·05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3·89, P < 0·001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4·92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5·294, P = 0·016) and lack of CR (HR 2·67, P < 0·001).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bastidas-Mora G, Beà S, Navarro A, et al. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. Br J Haematol. 2021. PMID: 34519021. doi:10.1111/bjh.17815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。